Federal Grand Jury Indicts Telehealth Firm Done Global in $100 Million Adderall Scheme

A federal grand jury in San Francisco has indicted California-based telehealth company Done Global Inc. and a Florida medical practice for allegedly orchestrating a scheme to illegally distribute over 40 million Adderall pills, generating more than $100 million in revenue. The Department of Justice announced the charges, which include conspiracy to distribute controlled substances, health care fraud, and obstruction of justice.

According to court documents, Done Global Inc. and Mindful Mental Wellness P.A. (MMW) utilized a subscription-based model to facilitate easy access to stimulants. Prosecutors allege that the companies conspired to instruct prescribers to authorize Adderall and other medications without legitimate medical purpose. The indictment claims the primary objective was to unlawfully enrich the defendants by boosting monthly subscription revenue and inflating the corporate value of Done Global.

U.S. Attorney Craig H. Missakian for the Northern District of California stated that the defendants are accused of exploiting telehealth technologies to prioritize profits over patient care. “Instead of leveraging technology to improve patient access to care and enhance communications, Done Global saw it as a way to boost profit. We will vigorously pursue companies that engage in this kind of fraud and put patients at risk,” Missakian said in a statement released by the Justice Department.

The indictment charges Done Global with conspiracy to illegally distribute Adderall, four counts of illegal distribution, conspiracy to commit health care fraud, and conspiracy to obstruct justice. Mindful Mental Wellness P.A. faces charges for participating in the conspiracy to illegally distribute Adderall. If convicted, both entities face significant financial penalties, potentially totaling twice the gross profits or twice the loss associated with the alleged fraud.

Regulatory Enforcement Outlook

This indictment signals a significant escalation in federal scrutiny regarding the digital health sector, particularly concerning the prescription of controlled substances via telehealth platforms following the relaxation of regulations during the pandemic. As the Department of Justice moves to hold corporate entities accountable for alleged exploitation of these systems, the outcome of this case could establish critical regulatory precedents for online medical providers. It is important to note that all individuals and entities named in the indictment are presumed innocent until proven guilty in a court of law.